Episode

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

Podcast
The IMID Forum
Published
May 15, 2026
Duration seconds
1315
Processing state
not_requested
Canonical source
https://soundcloud.com/imidforum/discussing-axspa-biologic
Audio
https://feeds.soundcloud.com/stream/2320500257-imidforum-discussing-axspa-biologic.mp3
JSON
/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-axspa-biologic-therapy-outcomes-in-axial-spondyloarthritis
Markdown
/podcast/the-imid-forum-981476/discussing-axspa-biologic-therapy-outcomes-in-axial-spondyloarthritis.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-axspa-biologic-therapy-outcomes-in-axial-spondyloarthritis/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-biologic-therapy-outcomes-in-axial-spondyloarthritis.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.